{"id":"NCT04089566","sponsor":"Biogen","briefTitle":"Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy","officialTitle":"Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-26","primaryCompletion":"2024-02-21","completion":"2024-05-30","firstPosted":"2019-09-13","resultsPosted":"2025-06-05","lastUpdate":"2025-06-05"},"enrollment":145,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Muscular Atrophy, Spinal"],"interventions":[{"type":"DRUG","name":"Nusinersen","otherNames":["BIIB058"]}],"arms":[{"label":"28/28 Milligram (mg) Safety Group","type":"EXPERIMENTAL"},{"label":"12/12 mg Active Control Group","type":"ACTIVE_COMPARATOR"},{"label":"50/28 mg Active Treatment Group","type":"EXPERIMENTAL"},{"label":"12/50/28 mg Titration Group","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C).\n\nThe secondary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A, B and C); to examine the effect of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA, to examine the effect of nusinersen administered intrathecally at higher doses compared to the currently approved dose in participants with SMA (Part B).","primaryOutcome":{"measure":"Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group","timeFrame":"Baseline, Day 183","effectByArm":[{"arm":"Part B: Infantile-Onset SMA: 50/28 mg Nusinersen","deltaMin":42.9,"sd":null},{"arm":"CS3B Matched Sham Control Group","deltaMin":16.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"7 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":45,"countries":["United States","Brazil","Canada","Chile","China","Colombia","Estonia","Germany","Hungary","Italy","Japan","Lebanon","Mexico","Poland","Russia","Saudi Arabia","Spain","Taiwan"]},"refs":{"pmids":["35567345"],"seeAlso":["http://www.sma-europe.eu/","http://www.curesma.org/","http://www.mda.org/disease/spinal-muscular-atrophy","https://www.biogentriallink.com/en-us/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["COVID-19","Procedural pain","Upper respiratory tract infection","Procedural headache","Pyrexia"]}}